Radiological and spirometric changes in relation to drugs used in post COVID pulmonary fibrosis in a cohort of COVID-19 survivors

Mohamed Hamoda, Amina Abd El-Maksoud, Aida M. Yousef, Dalia Monir Fahmy, Mohamed Tohlob
{"title":"Radiological and spirometric changes in relation to drugs used in post COVID pulmonary fibrosis in a cohort of COVID-19 survivors","authors":"Mohamed Hamoda, Amina Abd El-Maksoud, Aida M. Yousef, Dalia Monir Fahmy, Mohamed Tohlob","doi":"10.1186/s43168-024-00323-9","DOIUrl":null,"url":null,"abstract":"It has been proposed that prolonged use of anti-inflammatory and anti-fibrotic drugs diminish the probability of development of lung fibrosis. Prolonged low-dose corticosteroid may prevent remodeling of the lung in survivors. Pirfenidone and colchicine may exhibit anti-fibrotic and anti-inflammatory properties as well. This retrospective observational study was conducted at post COVID-19 clinic, Mansoura University Hospitals, during the period between October 2020 and March 2022. This study included 104 patients who had COVID-19 pneumonia confirmed either by RT-PCR or radiologically by CT scan and divided into 3 groups; group A (corticosteroids only) included 33 (31.7%) patients, group B (corticosteroids and colchicine) included 56 (53.8%) patients, and group C (corticosteroids, colchicine, and pirfenidone) included 15 (14.4%) patients. All patients were assessed during follow-up visits in post COVID-19 clinic 1 and 3 months after discharge by evaluation of resting SpO2, spirometry, and radiological assessment. Patients’ data during hospitalization was collected from hospital electronic systems. There was non-statistically significant improvement in FEV1 in group A while there was statistically significant improvement in FEV1 in groups B and C (P value = 0.002 and 0.041, respectively) 1 month and 3 months after discharge. Group B exhibited more statistically significant improvement in FVC as well compared to group C (P value = 0.003 and 0.025, respectively) while group A showed non-statistically significant improvement in FVC. There was a statistically significant decrease in CT severity score in all the groups during follow-up with P value < 0.001 in groups A and B and to less extent less statistically significant decrease in group C comparing the 3 groups to each other. The use of colchicine added to corticosteroids after acute phase of COVID-19 pneumonia resulted in statistically significant improvement regarding functional and radiological changes during follow-up when compared to corticosteroids alone. The addition of pirfenidone (which is a relatively expensive drug) to corticosteroids and colchicine did not add more statistically significant improvement in functional or radiological changes.\n","PeriodicalId":22426,"journal":{"name":"The Egyptian Journal of Bronchology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Egyptian Journal of Bronchology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43168-024-00323-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

It has been proposed that prolonged use of anti-inflammatory and anti-fibrotic drugs diminish the probability of development of lung fibrosis. Prolonged low-dose corticosteroid may prevent remodeling of the lung in survivors. Pirfenidone and colchicine may exhibit anti-fibrotic and anti-inflammatory properties as well. This retrospective observational study was conducted at post COVID-19 clinic, Mansoura University Hospitals, during the period between October 2020 and March 2022. This study included 104 patients who had COVID-19 pneumonia confirmed either by RT-PCR or radiologically by CT scan and divided into 3 groups; group A (corticosteroids only) included 33 (31.7%) patients, group B (corticosteroids and colchicine) included 56 (53.8%) patients, and group C (corticosteroids, colchicine, and pirfenidone) included 15 (14.4%) patients. All patients were assessed during follow-up visits in post COVID-19 clinic 1 and 3 months after discharge by evaluation of resting SpO2, spirometry, and radiological assessment. Patients’ data during hospitalization was collected from hospital electronic systems. There was non-statistically significant improvement in FEV1 in group A while there was statistically significant improvement in FEV1 in groups B and C (P value = 0.002 and 0.041, respectively) 1 month and 3 months after discharge. Group B exhibited more statistically significant improvement in FVC as well compared to group C (P value = 0.003 and 0.025, respectively) while group A showed non-statistically significant improvement in FVC. There was a statistically significant decrease in CT severity score in all the groups during follow-up with P value < 0.001 in groups A and B and to less extent less statistically significant decrease in group C comparing the 3 groups to each other. The use of colchicine added to corticosteroids after acute phase of COVID-19 pneumonia resulted in statistically significant improvement regarding functional and radiological changes during follow-up when compared to corticosteroids alone. The addition of pirfenidone (which is a relatively expensive drug) to corticosteroids and colchicine did not add more statistically significant improvement in functional or radiological changes.
COVID-19幸存者组群的放射学和肺活量变化与COVID后肺纤维化所用药物的关系
有研究认为,长期服用抗炎和抗纤维化药物可降低肺纤维化发生的概率。长期服用小剂量皮质类固醇可防止幸存者肺部重塑。吡非尼酮和秋水仙碱也可能具有抗纤维化和抗炎作用。这项回顾性观察研究于 2020 年 10 月至 2022 年 3 月期间在曼苏尔大学医院 COVID-19 后诊所进行。该研究纳入了 104 名经 RT-PCR 或 CT 扫描放射学证实患有 COVID-19 肺炎的患者,并将其分为 3 组:A 组(仅皮质类固醇)包括 33 名(31.7%)患者,B 组(皮质类固醇和秋水仙碱)包括 56 名(53.8%)患者,C 组(皮质类固醇、秋水仙碱和吡非尼酮)包括 15 名(14.4%)患者。所有患者均在出院后 1 个月和 3 个月在 COVID-19 后诊所接受随访,评估静息 SpO2、肺活量和放射学评估。患者住院期间的数据由医院电子系统收集。A 组患者的 FEV1 改善无统计学意义,而 B 组和 C 组患者出院 1 个月和 3 个月后的 FEV1 改善有统计学意义(P 值分别为 0.002 和 0.041)。与 C 组相比,B 组在 FVC 方面的改善更具有统计学意义(P 值分别为 0.003 和 0.025),而 A 组在 FVC 方面的改善无统计学意义。在随访期间,A 组和 B 组的 CT 严重程度评分均有统计学意义上的明显降低,P 值均小于 0.001,而 C 组的 CT 严重程度评分的下降幅度较小,三组间比较无统计学意义。与单独使用皮质类固醇相比,COVID-19 肺炎急性期后在使用皮质类固醇的基础上加用秋水仙碱,可在随访期间明显改善功能和放射学变化。在皮质类固醇和秋水仙碱的基础上添加吡非尼酮(一种相对昂贵的药物),并没有在功能和放射学变化方面带来更多统计学意义上的明显改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信